Johnson & Johnson (NYSE:JNJ) Shares Sold by Aletheian Wealth Advisors LLC

Posted by Defense World Staff on Aug 30th, 2023

Aletheian Wealth Advisors LLC lowered its holdings in shares of Johnson & Johnson (NYSE:JNJ – Free Report) by 54.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,826 shares of the company’s stock after selling 2,145 shares during the period. Aletheian Wealth Advisors LLC’s holdings in Johnson & Johnson were worth $283,000 as of its most recent SEC filing.

A number of other large investors have also recently bought and sold shares of JNJ. Moneta Group Investment Advisors LLC raised its position in Johnson & Johnson by 90,144.4% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock worth $9,607,414,000 after buying an additional 54,326,454 shares during the last quarter. Geode Capital Management LLC raised its position in Johnson & Johnson by 0.6% during the 4th quarter. Geode Capital Management LLC now owns 47,958,583 shares of the company’s stock worth $8,456,643,000 after buying an additional 294,671 shares during the last quarter. Morgan Stanley raised its position in Johnson & Johnson by 12.0% during the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Johnson & Johnson by 15.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock valued at $5,171,919,000 after purchasing an additional 3,849,148 shares in the last quarter. Finally, Norges Bank purchased a new position in shares of Johnson & Johnson in the 4th quarter valued at about $4,609,399,000. Institutional investors and hedge funds own 68.40% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Atlantic Securities increased their price target on shares of Johnson & Johnson from $167.00 to $170.00 and gave the company a “neutral” rating in a report on Friday, August 4th. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a report on Monday, August 21st. Stifel Nicolaus increased their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. Credit Suisse Group increased their price target on shares of Johnson & Johnson from $170.00 to $175.00 and gave the company a “neutral” rating in a report on Friday, July 21st. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a report on Tuesday, August 22nd. Eight investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $171.80.

View Our Latest Stock Analysis on JNJ

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $164.31 on Wednesday. Johnson & Johnson has a 12-month low of $150.11 and a 12-month high of $181.04. The stock has a market capitalization of $427.04 billion, a P/E ratio of 33.26, a P/E/G ratio of 2.76 and a beta of 0.54. The firm’s 50-day moving average is $166.68 and its two-hundred day moving average is $161.50. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88.

Johnson & Johnson (NYSE:JNJ – Get Free Report) last released its quarterly earnings results on Thursday, July 20th. The company reported $2.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.62 by $0.18. Johnson & Johnson had a net margin of 13.35% and a return on equity of 36.72%. The company had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same period last year, the company earned $2.59 EPS. The firm’s revenue for the quarter was up 6.3% compared to the same quarter last year. Equities analysts predict that Johnson & Johnson will post 10.75 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 7th. Investors of record on Monday, August 28th will be given a $1.19 dividend. The ex-dividend date of this dividend is Friday, August 25th. This represents a $4.76 annualized dividend and a dividend yield of 2.90%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

Insider Buying and Selling

In related news, insider William Hait sold 14,698 shares of the firm’s stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total value of $2,528,056.00. Following the sale, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Johnson & Johnson news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at $15,092,484. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Kathryn E. Wengel sold 12,465 shares of Johnson & Johnson stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the transaction, the executive vice president now directly owns 65,934 shares in the company, valued at $10,549,440. The disclosure for this sale can be found here. Over the last three months, insiders have sold 47,163 shares of company stock valued at $7,928,856. Insiders own 0.20% of the company’s stock.

Johnson & Johnson Profile

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.